查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1782004

胃腸治療市場，按藥物類型、按藥物類型、按劑型、按應用、按配銷通路、按國家/地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Gastrointestinal Therapeutics Market, By Medication Type, By Drug Type, By Dosage Form, By Application, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 284 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年胃腸治療市場規模價值 402.0911 億美元，2025 年至 2032 年期間的複合年成長率為 5.50%。

胃腸治療市場-市場動態

生物製劑的進步提高了治療效果和採用率

生物製劑的進步帶來了更具針對性和有效性的療法，徹底改變了胃腸道疾病的治療方式。這些療法透過特異性調節免疫系統發揮作用，從而比傳統藥物更有效地控制發炎和症狀。艾伯維的修美樂（阿達木單抗）是一種廣泛用於治療克隆氏症和潰瘍性結腸炎的生物製劑，其標靶療法顯著改善了患者的預後，充分體現了生物製劑的成功。生物相似藥的推出進一步促進了生物製劑的成長，使其更易於獲取且價格更親民，從而推動了胃腸道治療市場對生物製劑的整體應用。

例如，

2024年3月，輝瑞推出了熱門生物製劑的生物相似藥，擴大了在胃腸道治療市場的佔有率。這些生物相似藥的療效和安全性與原廠生物製劑相當，但成本更低，使更廣泛的患者群體，尤其是在成本敏感的市場，更容易獲得先進的治療方案。

2023年9月，強生公司推出了旨在治療發炎性腸道疾病的創新生物療法。他們的新產品專注於針對特定的免疫途徑，以更有效地減輕炎症，為患者提供可能改善長期疾病管理和療效的新選擇。

這些持續的創新和生物製劑的擴大應用預計將推動胃腸道治療市場的顯著成長和患者治療效果的改善。

胃腸治療市場—關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 5.50%。

根據藥物類型細分，預計品牌藥物將在 2024 年佔據最大市場佔有率

根據藥物類型細分，生物製劑/生物相似藥是 2024 年的主要藥物類型

根據劑型細分，口服是 2024 年的主要劑型

根據應用細分，胃食道逆流症 (GERD) 是 2024 年的主要應用

根據配銷通路細分，醫院藥房是2024年的主要配銷通路

按地區分類，北美是 2024 年的主要收入來源

胃腸治療市場-細分分析：

全球胃腸治療市場根據藥物類型、藥物類型、劑型、應用、配銷通路和地區進行細分。

根據藥物類型，市場分為兩類：品牌藥和學名藥。品牌藥領域佔市場主導地位。這得益於醫生對成熟且經過臨床驗證的藥物的強烈偏好，積極的市場行銷和品牌認知度推動了學名藥的高採用率，以及針對克隆氏症、潰瘍性結腸炎和腸易激症候群等複雜胃腸道疾病的創新製劑的供應。此外，專利保護和監管排他性限制了學名藥在某些治療領域的滲透，尤其是在對先進和專業治療需求更高的已開發地區。

根據應用，市場分為五類：克隆氏症、胃食道逆流症 (GERD)、腸躁症 (IBS)、潰瘍性結腸炎等。胃食道逆流症 (GERD) 是胃腸道治療市場的主要應用領域。這主要歸因於其全球盛行率高，尤其是在已開發地區，以及該疾病的慢性性質，通常需要長期或終身治療。質子幫浦抑制劑 (PPI) 和 H2 受體拮抗劑的廣泛使用，再加上肥胖、不良飲食和壓力等生活方式相關因素導致的診斷率上升，進一步增強了 GERD 在該市場的主導地位。此外，強大的藥物管道和針對 GERD 的持續產品創新為其領先的市場佔有率做出了重要貢獻。

胃腸治療市場—地理洞察

在 2024 年的預測期內，北美將主導全球胃腸治療市場。

北美引領胃腸道治療市場，憑藉其先進的醫療基礎設施和高昂的醫療支出佔據最大佔有率。該地區胃腸道疾病（例如胃食道逆流症 (GERD)、腸躁症 (IBS) 和克隆氏症）的發生率較高，因此對有效療法的需求強勁。大型製藥公司的佈局、完善的監管框架以及創新藥物的廣泛可及性進一步促進了市場成長。較高的認知度、早期診斷和優惠的報銷政策也鞏固了該地區的主導地位。美國是北美市場的主要驅動力，得益於持續的研發投入和新型治療方案的快速應用。

預計在 2024 年的預測期內，亞太地區的胃腸治療市場複合年成長率最高。

亞太地區是胃腸道治療市場成長最快的地區，其驅動力源自於人口規模龐大且老化加劇，胃腸道疾病的盛行率也隨之上升。快速的城市化、生活方式的改變以及飲食結構的轉變，導致胃食道逆流症 (GERD) 和腸躁症 (IBS) 等疾病的發生率上升。不斷成長的醫療保健投資、政府舉措以及醫療服務可近性的不斷擴大，正在推動中國、印度和韓國等國家市場的發展。由於該地區尚未開發的潛力以及對價格實惠、高品質治療藥物日益成長的需求，製藥公司越來越關注該地區。認知度的提高和醫療保健基礎設施的完善，正在進一步加速該地區的成長。

胃腸治療市場-競爭格局：

胃腸道治療市場競爭激烈，許多全球及地區性企業積極參與創新療法的研發與商業化。艾伯維公司、武田製藥有限公司、強生公司、輝瑞公司和阿斯特捷利康等主要公司憑藉強大的產品組合佔據市場主導地位，這些產品組合針對克隆氏症、潰瘍性結腸炎、胃食道逆流（GERD）和腸躁症（IBS）等主要胃腸道疾病。這些企業專注於策略合作、併購和廣泛的研發，以維持市場地位並擴展其治療產品。

同時，大量新興生技公司紛紛進軍此領域，致力於研發療效更佳、安全性更高的尖端生物製劑及小分子藥物。生物相似藥和學名藥的日益普及也加劇了價格競爭，尤其是在發展中市場。各大公司正投入資源，擴大全球影響力，爭取監管部門的批准，並推出先進的給藥系統，以維持領先地位。簡而言之，創新、強大的產品線和地理擴張是塑造該市場競爭格局的驅動力。

最新動態：

2025年2月，Zydus Lifesciences獲得美國FDA核准生產布洛芬和法莫替丁錠劑。這些片劑旨在治療類風濕性關節炎和骨關節炎，同時降低上消化道潰瘍的風險。此項批准旨在擴大Zydus的消化道產品組合，以減輕消化性潰瘍患者的負擔。

2025年4月，艾爾建公司完成了對Viral Burn的收購。 Viral Burn是一家專注於開發新型胃腸道疾病療法的私人生物技術公司。此次收購將Viral Burn的主導產品VB-201納入艾爾建的產品線。 VB-201是一種用於治療諾羅病毒性胃腸炎的首創口服非全身性抗病毒療法。

2021年4月，梯瓦製藥美國公司（Teva Pharmaceuticals USA）在美國推出了其1000毫克Casana（美沙拉嗪）栓劑學名藥，用於治療活動性潰瘍性直腸炎成人患者。這款價格實惠的學名藥的推出提高了治療的可及性，並透過提供經濟高效的選擇，使梯瓦在胃腸道疾病市場佔據了強勢地位。此外，隨著潰瘍性結腸炎盛行率不斷上升，該學名藥也有助於公司抓住這一機遇，並抓住治療需求不斷成長的機會。

目錄

第1章：胃腸治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 胃腸治療市場（按藥物類型）
    • 胃腸治療市場（按藥物類型）
    • 胃腸治療市場（按劑型）摘要
    • 胃腸治療市場片段（按應用）
    • 胃腸治療市場按配銷通路分類
    • 胃腸治療市場（按國家/地區）
    • 胃腸治療市場（按地區）
  • 競爭洞察

第3章：胃腸治療關鍵市場趨勢

  • 胃腸治療市場促進因素
    • 市場促進因素的影響分析
  • 胃腸道治療市場限制
    • 市場限制的影響分析
  • 胃腸治療市場機遇
  • 胃腸治療市場未來趨勢

第4章：胃腸治療產業研究

  • PESTEL分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：胃腸治療市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：胃腸治療市場格局

  • 2024年胃腸治療市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：胃腸治療市場－依藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 品牌
    • 泛型

第 8 章：胃腸道治療市場 - 按藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 抗酸藥
    • 止吐藥
    • 止瀉藥
    • 抗潰瘍藥
    • 抗生素
    • 生物製劑/生物相似藥
    • 瀉藥
    • 質子幫浦抑制劑（PPI）
    • 其他藥物類型

第9章：胃腸治療市場－按劑型

  • 概述
    • 按劑型分類的細分市場佔有率分析
    • 口服
    • 腸外

第 10 章：胃腸治療市場 - 按應用

  • 概述
    • 按應用細分市場佔有率分析
    • 克隆氏症
    • 胃食道逆流症（GERD）
    • 腸躁症（IBS）
    • 潰瘍性結腸炎
    • 其他

第 11 章：胃腸治療市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 12 章：胃腸治療市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美胃腸治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按藥物類型）
    • 北美市場規模及預測（依藥品類型）
    • 北美市場規模及預測（按劑型）
    • 北美市場規模和預測（按應用）
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲胃腸治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（按藥物類型）
    • 歐洲市場規模及預測（依藥品類型）
    • 歐洲市場規模及預測（按劑型）
    • 歐洲市場規模和預測，按應用
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區胃腸治療主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依藥物類型）
    • 亞太地區市場規模及預測（依藥品類型）
    • 亞太地區市場規模及預測（依劑型分類）
    • 亞太地區市場規模及預測（按應用）
    • 亞太地區市場規模及預測（按配銷通路）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲胃腸治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按藥物類型）
    • 拉丁美洲市場規模及預測（按藥物類型）
    • 拉丁美洲市場規模及預測（以劑型分類）
    • 拉丁美洲市場規模及預測（按應用）
    • LATAM 規模及預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲胃腸治療主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按藥物類型）
    • 中東和非洲市場規模及預測（依藥品類型）
    • 中東和非洲市場規模及預測（按劑型）
    • 中東和非洲市場規模和預測（按應用）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 13 章：胃腸治療產業主要供應商分析

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corp.
    • Cipla
    • Eisai Co. Ltd.
    • Eli Lilly and Co.
    • Evoke Pharma Inc.
    • GlaxoSmithKline Plc
    • Johnson and Johnson Services Inc.
    • Merck and Co. Inc.
    • Novartis AG
    • Olympus Corp.
    • Ovesco Endoscopy AG
    • Pfizer Inc.
    • Salix Pharmaceuticals Inc.
    • Takeda Pharmaceutical Co. Ltd.
    • UCB SA
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5444

REPORT HIGHLIGHT

Gastrointestinal Therapeutics Market size was valued at US$ 40,209.11 Million in 2024, expanding at a CAGR of 5.50% from 2025 to 2032.

The Gastrointestinal Therapeutics Market is all about producing, and distributing medications aimed at tackling issues related to the digestive system. This includes a variety of conditions like Crohn's disease, ulcerative colitis, GERD, IBS, and various infections that can affect the gastrointestinal (GI) tract. The market features a broad spectrum of treatments, such as antacids, biologics, anti-diarrheal, proton pump inhibitors, laxatives, and antibiotics, which can be administered through both oral and injectable forms. The growing demand in this sector is largely fueled by the increasing rates of GI diseases, lifestyle related digestive problems, and the latest advancements in targeted therapies and biologics. Both branded and generic medications play a role in this market, which is primarily supplied through hospitals, retail outlets, and online pharmacies.

Gastrointestinal Therapeutics Market- Market Dynamics

Advancements in biologics enhance therapeutic effectiveness and adoption

Advancements in biologics have transformed the treatment of gastrointestinal disorders by offering more targeted and effective therapies. These treatments work by specifically modulating the immune system, which helps control inflammation and manage symptoms better than traditional drugs. AbbVie's Humira (adalimumab), a biologic drug widely used for Crohn's disease and ulcerative colitis, exemplifies this success with its targeted approach significantly improving patient outcomes. The introduction of biosimilar versions has further supported this growth by making these therapies more accessible and affordable, boosting the overall adoption of biologic therapies in the gastrointestinal therapeutics market.

for instance,

In March 2024, Pfizer expanded its presence in the GI therapeutics market by launching biosimilar versions of popular biologics. These biosimilars offer comparable efficacy and safety to original biologics but at a lower cost, making advanced treatments more accessible to a wider patient population, especially in cost sensitive markets.

In September 2023, Johnson & Johnson introduced innovative biologic therapies aimed at treating inflammatory bowel diseases. Their new products focus on targeting specific immune pathways to reduce inflammation more effectively, providing patients with new options that could potentially improve long-term disease management and outcomes.

These continuous innovations and expanded access to biologics are expected to drive significant growth and improved patient outcomes in the gastrointestinal therapeutics market.

Gastrointestinal Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2025-2032)

Based on medication type segmentation, branded was predicted to show maximum market share in the year 2024

Based on drug type segmentation, biologics/ biosimilars was the leading drug type in 2024

Based on dosage form segmentation, oral was the leading dosage form in 2024

Based on application segmentation, gastroesophageal reflux disease (GERD) was the leading application in 2024

Based on distribution channel segmentation, hospital pharmacies was the leading distribution channel in 2024

On the basis of region, North America was the leading revenue generator in 2024

Gastrointestinal Therapeutics Market- Segmentation Analysis:

The global gastrointestinal therapeutics market is segmented on the basis of medication type, drug type, dosage form, application, distribution channel, and region.

The market is divided into two categories based on medication type: Branded, and Generics. The Branded sector dominates the market. Due to strong physician preference for established, clinically validated drugs, high adoption driven by aggressive marketing and brand recognition, and the availability of innovative formulations targeting complex GI conditions such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome. Additionally, patent protections and regulatory exclusivity have limited the penetration of generics in certain therapeutic segments, especially in developed regions where there is a higher demand for advanced and specialized treatments.

The market is divided into five categories based on application: crohn's disease, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), ulcerative colitis, others. Gastroesophageal Reflux Disease (GERD) represents the dominating application segment in the gastrointestinal therapeutics market. This is largely attributed to its high global prevalence, especially in developed regions, and the chronic nature of the condition, which often requires long-term or lifelong management. The widespread use of proton pump inhibitors (PPIs) and H2 receptor antagonists, coupled with increasing diagnosis rates due to lifestyle-related factors such as obesity, poor diet, and stress, further fuels the dominance of GERD in this market. Additionally, strong pharmaceutical pipelines and continuous product innovation targeting GERD contribute significantly to its leading market share.

Gastrointestinal Therapeutics Market- Geographical Insights

North America dominates the global gastrointestinal therapeutics market during the forecast period in 2024.

North America leads the gastrointestinal therapeutics market, accounting for the largest share due to its advanced healthcare infrastructure and high healthcare spending. The region experiences a significant burden of gastrointestinal disorders such as GERD, IBS, and Crohn's disease, which drives strong demand for effective therapies. The presence of major pharmaceutical companies, a well-established regulatory framework, and widespread access to innovative drugs further enhance market growth. High awareness levels, early diagnosis, and favourable reimbursement policies also contribute to the region's dominance. The United States is the primary driver within North America, supported by ongoing R&D investments and rapid adoption of novel treatment options.

Asia Pacific is estimated to register the highest CAGR in the gastrointestinal therapeutics market during the forecast period in 2024.

Asia-Pacific is the fastest growing region in the gastrointestinal therapeutics market, driven by a large and aging population with increasing prevalence of GI disorders. Rapid urbanization, lifestyle changes, and dietary shifts are contributing to a higher incidence of diseases such as GERD and IBS. Growing healthcare investments, government initiatives, and expanding access to medical care are supporting market development across countries like China, India, and South Korea. Pharmaceutical companies are increasingly focusing on this region due to its untapped potential and rising demand for affordable, high-quality therapeutics. Improved awareness and healthcare infrastructure are further accelerating growth across the region.

Gastrointestinal Therapeutics Market- Competitive Landscape:

The gastrointestinal therapeutics market is highly competitive, with the presence of several global and regional players actively engaged in research, development, and commercialization of innovative treatments. Key companies such as AbbVie Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Pfizer Inc., and AstraZeneca dominate the market with strong product portfolios targeting major GI disorders like Crohn's disease, ulcerative colitis, GERD, and IBS. These players focus on strategic collaborations, mergers & acquisitions, and extensive R&D to maintain their market positions and expand their therapeutic offerings.

At the same time, there's a surge of emerging biotech firms stepping into the ring, working on cutting-edge biologics and small molecules that promise better efficacy and safety. The growing presence of biosimilars and generic drugs is also ramping up price competition, especially in developing markets. Companies are pouring resources into expanding their global reach, securing regulatory approvals, and rolling out advanced drug delivery systems to stay ahead of the game. In a nutshell, innovation, a strong pipeline, and geographic expansion are the driving forces shaping the competitive landscape of this market.

Recent Developments:

In February 2025, Zydus Lifesciences received U.S. FDA approval for the production Ibuprofen and Famotidine tablets. These tablets were designed to treat rheumatoid arthritis and osteoarthritis while reducing the risk of upper GI ulcers. This approval aimed to broaden Zydus's GI portfolio addressing the burden of peptic ulcer cases

In April 2025, Allergan plc completed the acquisition of Viral Burn, a privately-held biotechnology company focused on developing novel therapeutics for gastrointestinal diseases. The acquisition adds Viral Burn's lead asset, VB-201, a first in class, oral, non-systemic antiviral therapy for the treatment of norovirus gastroenteritis, to Allergan's pipeline

In April 2021, Teva Pharmaceuticals USA launched its 1000 mg generic version of Casana (mesalamine) suppository for treating adults with active ulcerative proctitis in the U.S. The introduction of this affordable generic alternative increases treatment accessibility and positions Teva strongly in the GI market by offering cost-effective options. It also helps the company capitalize on the growing demand for ulcerative colitis treatments amid rising prevalence

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corp.
  • Cipla
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Evoke Pharma Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Olympus Corp.
  • Ovesco Endoscopy AG
  • Pfizer Inc.
  • Salix Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA
  • Others

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY MEDICATION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded
  • Generics

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antacids
  • Antiemetics
  • Antidiarrheals
  • Antiulcer agents
  • Antibiotics
  • Biologics/ biosimilars
  • Laxatives
  • Proton pump inhibitors (PPIs)
  • Other drug types

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Crohn's disease
  • Gastroesophageal reflux disease (GERD)
  • Irritable Bowel Syndrome (IBS)
  • Ulcerative colitis
  • Others

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gastrointestinal Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gastrointestinal Therapeutics Market Snippet by Medication Type
    • 2.1.2. Gastrointestinal Therapeutics Market Snippet by Drug Type
    • 2.1.3. Gastrointestinal Therapeutics Market Snippet by Dosage Form
    • 2.1.4. Gastrointestinal Therapeutics Market Snippet by Application
    • 2.1.5. Gastrointestinal Therapeutics Market Snippet by Distribution Channel
    • 2.1.6. Gastrointestinal Therapeutics Market Snippet by Country
    • 2.1.7. Gastrointestinal Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Gastrointestinal Therapeutics Key Market Trends

  • 3.1. Gastrointestinal Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gastrointestinal Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gastrointestinal Therapeutics Market Opportunities
  • 3.4. Gastrointestinal Therapeutics Market Future Trends

4. Gastrointestinal Therapeutics Industry Study

  • 4.1. PESTEL Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gastrointestinal Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gastrointestinal Therapeutics Market Landscape

  • 6.1. Gastrointestinal Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gastrointestinal Therapeutics Market - By Medication Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Medication Type, 2024 & 2032 (%)
    • 7.1.2. Branded
    • 7.1.3. Generics

8. Gastrointestinal Therapeutics Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 8.1.2. Antacids
    • 8.1.3. Antiemetics
    • 8.1.4. Antidiarrheals
    • 8.1.5. Antiulcer agents
    • 8.1.6. Antibiotics
    • 8.1.7. Biologics/ biosimilars
    • 8.1.8. Laxatives
    • 8.1.9. Proton pump inhibitors (PPIs)
    • 8.1.10. Other drug types

9. Gastrointestinal Therapeutics Market - By Dosage Form

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Parenteral

10. Gastrointestinal Therapeutics Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Crohn's disease
    • 10.1.3. Gastroesophageal reflux disease (GERD)
    • 10.1.4. Irritable Bowel Syndrome (IBS)
    • 10.1.5. Ulcerative colitis
    • 10.1.6. Others

11. Gastrointestinal Therapeutics Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Online pharmacies

12. Gastrointestinal Therapeutics Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gastrointestinal Therapeutics Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gastrointestinal Therapeutics Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gastrointestinal Therapeutics Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Gastrointestinal Therapeutics Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gastrointestinal Therapeutics Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Medication Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gastrointestinal Therapeutics Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Abbott Laboratories
    • 13.2.2. AbbVie Inc.
    • 13.2.3. AstraZeneca Plc
    • 13.2.4. Bayer AG
    • 13.2.5. Biogen Inc.
    • 13.2.6. Boehringer Ingelheim International GmbH
    • 13.2.7. Boston Scientific Corp.
    • 13.2.8. Cipla
    • 13.2.9. Eisai Co. Ltd.
    • 13.2.10. Eli Lilly and Co.
    • 13.2.11. Evoke Pharma Inc.
    • 13.2.12. GlaxoSmithKline Plc
    • 13.2.13. Johnson and Johnson Services Inc.
    • 13.2.14. Merck and Co. Inc.
    • 13.2.15. Novartis AG
    • 13.2.16. Olympus Corp.
    • 13.2.17. Ovesco Endoscopy AG
    • 13.2.18. Pfizer Inc.
    • 13.2.19. Salix Pharmaceuticals Inc.
    • 13.2.20. Takeda Pharmaceutical Co. Ltd.
    • 13.2.21. UCB SA
    • 13.2.22. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us